PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC
Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/12/15 - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gyorgi Keri is the founder of Vichem Chemie Res. Ltd and is a Professor at Semmelweis University. He got his PhD from biochemistry in Budapest, and was post doc. at University of California, San Francisco.

He has been working together with Professor Axel Ullrich (Max Planck Institute) for more than 25 years on developing kinase inhibitors. He was advisor and collaborative partner of SUgen Inc. from 1992 to 1999 and Axxima Pharmaceuticals from 1999 to 2005.

He has been involved in the development of several kinase inhibitors which have been licensed for external partners. He also developed the Nested Chemical Library™ (NCL) technology, based on a knowledge based approach where focused libraries of kinase inhibitors around more than 600 scaffolds are used for hit finding and to generate pharmacophore models.

Using the NCL™ kinase inhibitor library, Vichem has developed, and will further develop, kinase inhibitors which kill more than 95% of certain cancer cells (including cancer stem cells). The goal is to provide a personalized therapy and molecular diagnostic protocol to select who will respond to a particular cancer stem cell killing drug.

The Protein Kinases in Drug Discovery Conference Europe, to be held on May 8-9, 2014, in Berlin, Germany, will be a premier conference that will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field. A balance of both academic and industry experts will facilitate discussion on validation of novel drug targets, current progress in drug design, kinases inhibitor development, and preclinical models and clinical development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)